The RE-TyPE study, sponsored by Sahlgrenska University Hospital, aims to enhance the understanding of intermediate-high risk pulmonary embolism (PE) through a comprehensive analysis of dynamic clinical parameters and biomarkers. This study addresses a significant unmet need in the management of PE, particularly in the intermediate-high risk group, where current risk stratification tools have shown limited predictive value. The findings could lead to improved patient outcomes and potentially inform new therapeutic strategies, positioning Sahlgrenska University Hospital as a leader in PE research. The establishment of a longitudinal follow-up platform may also facilitate future collaborations and funding opportunities, enhancing the hospital's reputation and commercial viability in the cardiovascular research space.